Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-881 vs HYQVIA in CIDP
NCT06747351Phase 3Recruiting
- Sponsor
- Takeda
- Start
- May 2025
- Primary completion
- Jun 2028
- Modality
- SC (Subcutaneous administration)
- Countries
- 11
01
Overview
A Phase 3 trial of TAK-881 in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), sponsored by Takeda. Started May 2025; status: recruiting.
02
Drugs
TAK-881
03
Conditions
chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)
Beyond the preview
Go deeper on NCT06747351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06747351.